Polygenic hazard score is associated with prostate cancer in multi-ethnic populations

Minh-Phuong Huynh-Le^{1,2}, Chun Chieh Fan², Roshan Karunamuni^{1,2} Wesley K Thompson^{3,4} Maria Elena Martinez⁵. Rosalind A Eeles^{6,7}. Zsofia Kote-Jarai⁶, Kenneth Muir^{8,9} UKGPCS collaborators ¹⁰ Johanna Schleutker^{11,12} Nora Pashayan^{13,14,15}, Jyotsna Batra^{16,17}, APCB (Australian Prostate Cancer BioResource)^{18,19} Henrik Grönberg²⁰ David E Neal^{21,22,23} Jenny L Donovan²⁴ Freddie C Hamdy^{25,26} Richard M Martin^{24,27,28} Sune F Nielsen^{29,30} Børge G Nordestgaard^{31,32}, Fredrik Wiklund³³ Catherine M Tangen³⁴ Graham G Giles^{35,36,37}. Alicja Wolk^{38,39} Demetrius Albanes⁴⁰. Ruth C Travis⁴¹. William J Blot^{42,43}. Wei Zheng⁴⁴, Maureen Sanderson⁴⁵ Janet L Stanford^{46,47} Lorelei A Mucci⁴⁸, Catharine M L West⁴⁹ Adam S Kibel⁵⁰, Olivier Cussenot^{51,52} Sonia I Berndt⁵³ Stella Koutros⁵³. Karina Dalsgaard Sørensen^{54,55}. Cezary Cybulski⁵⁶ Eli Marie Grindedal⁵⁷. Florence Menegaux^{58,59} Kay-Tee Khaw⁶⁰ Jong Y Park⁶¹. Sue A Ingles⁶², Christiane Maier⁶³.

Robert J Hamilton^{64,65} Stephen N Thibodeau⁶⁶ Barry S Rosenstein^{67,68}, Yong-Jie Lu⁶⁹, Stephen Watya⁷⁰ Ana Vega^{71,72,73}, NC-LA PCaP Investigators 74,75,76 The IMPACT Study Steering Committee and Collaborators 77, Manolis Kogevinas^{78,79,80}, Kathryn L Penney⁸¹, Chad Huff⁸². Manuel R Teixeira^{83,84}, Luc Multigner⁸⁵ Robin J Leach⁸⁶, Lisa Cannon-Albright^{87,88} Hermann Brenner^{89,90,91}. Esther M John⁹² Radka Kaneva⁹³, Christopher J Logothetis⁹⁴, Susan L Neuhausen⁹⁵, Kim De Ruyck⁹⁶, Hardev Pandha⁹⁷. Azad Razack⁹⁸, Lisa F Newcomb^{46,99}. Canary PASS Investigators 46,99, Jay Fowke¹⁰⁰. Marija Gamulin¹⁰¹. Nawaid Usmani^{102,103} Frank Claessens¹⁰⁴, Manuela Gago-Dominguez^{105,106}, Paul A Townsend¹⁰⁷, William S Bush¹⁰⁸, Shiv Srivastava^{109,110}, Monique J Roobol¹¹¹, Marie- Élise Parent^{112,113} Jennifer J Hu¹¹⁴, The Profile Study Steering Committee ¹¹⁵, Ian G Mills¹¹⁶. Ole A Andreassen¹¹⁷, Anders M Dale¹¹⁸. Tyler M Seibert^{1,2,119}. The PRACTICAL Consortium *

¹Department of Radiation Medicine and Applied Sciences, University of California San Diego, La Jolla, CA, USA ²Center for Multimodal Imaging and Genetics, University of California, San Diego, La Jolla, CA, USA

³Division of Biostatistics and Halicioğlu Data Science Institute, University of California San Diego

⁴Department of Family Medicine and Public Health, University of California San Diego ⁵University of California San Diego, Moores Cancer Center, Department of Family Medicine and Public Health, University of California San Diego, La Jolla, CA 92093-0012, USA ⁶The Institute of Cancer Research, London, SM2 5NG, UK

⁷Royal Marsden NHS Foundation Trust, London, SW3 6JJ, UK

⁸Division of Population Health, Health Services Research and Primary Care, University of

Manchester, Oxford Road, Manchester, M13 9PL, UK

⁹Warwick Medical School, University of Warwick, Coventry, UK

¹⁰http://www.icr.ac.uk/our-research/research-divisions/division-of-genetics-and-

epidemiology/oncogenetics/research-projects/ukgpcs/ukgpcs-collaborators

¹¹Institute of Biomedicine, Kiinamyllynkatu 10, FI-20014 University of Turku, Finland

¹²Department of Medical Genetics, Genomics, Laboratory Division, Turku University Hospital, PO Box 52, 20521 Turku, Finland

¹³University College London, Department of Applied Health Research, London, UK

¹⁴Centre for Cancer Genetic Epidemiology, Department of Oncology, University of Cambridge, Strangeways Laboratory, Worts Causeway, Cambridge, CB1 8RN, UK

¹⁵Department of Applied Health Research, University College London, London, WC1E 7HB, UK

¹⁶Australian Prostate Cancer Research Centre-Qld, Institute of Health and Biomedical Innovation and School of Biomedical Sciences, Queensland University of Technology, Brisbane QLD 4059, Australia

¹⁷Translational Research Institute, Brisbane, Queensland 4102, Australia

¹⁸Australian Prostate Cancer Research Centre-Qld, Queensland University of Technology, Brisbane; Prostate Cancer Research Program, Monash University, Melbourne; Dame Roma Mitchell Cancer Centre, University of Adelaide, Adelaide; Chris O'Brien Lifehouse and The Kinghorn Cancer Centre, Sydney, Australia

¹⁹Translational Research Institute, Brisbane, Queensland, Australia

²⁰Department of Medical Epidemiology and Biostatistics, Karolinska Institute, Stockholm, Sweden

²¹Nuffield Department of Surgical Sciences, University of Oxford, Room 6603, Level 6, John Radcliffe Hospital, Headley Way, Headington, Oxford, OX3 9DU, UK

²²University of Cambridge, Department of Oncology, Box 279, Addenbrooke's Hospital, Hills Road, Cambridge CB2 0QQ, UK

²³Cancer Research UK, Cambridge Research Institute, Li Ka Shing Centre, Cambridge UK
²⁴Population Health Sciences, Bristol Medical School, University of Bristol, BS8 2PS, UK

²⁵Nuffield Department of Surgical Sciences, University of Oxford, OX1 2JD, UK

²⁶Faculty of Medical Science, University of Oxford, John Radcliffe Hospital, Oxford, UK

²⁷National Institute for Health Research (NIHR) Biomedical Research Centre, University of Bristol, Bristol, BS8 1TH, UK

²⁸Medical Research Council (MRC) Integrative Epidemiology Unit, University of Bristol, Bristol, BS8 2BN, UK.

²⁹Faculty of Health and Medical Sciences, University of Copenhagen, 2200 Copenhagen, Denmark

³⁰Department of Clinical Biochemistry, Herlev and Gentofte Hospital, Copenhagen University Hospital, Herlev, 2200 Copenhagen, Denmark

³¹Faculty of Health and Medical Sciences, University of Copenhagen, 2200 Copenhagen, Denmark

³²Department of Clinical Biochemistry, Herlev and Gentofte Hospital, Copenhagen University Hospital, Herlev, 2200 Copenhagen, Denmark

³³Department of Medical Epidemiology and Biostatistics, Karolinska Institute, SE-171 77 Stockholm, Sweden

³⁴SWOG Statistical Center, Fred Hutchinson Cancer Research Center, Seattle, WA, USA

³⁵Cancer Epidemiology Division, Cancer Council Victoria, 615 St Kilda Road, Melbourne, VIC 3004, Australia

³⁶Centre for Epidemiology and Biostatistics, Melbourne School of Population and Global Health, The University of Melbourne, Grattan Street, Parkville, VIC 3010, Australia

³⁷Precision Medicine, School of Clinical Sciences at Monash Health, Monash University, Clayton, Victoria 3168, Australia

³⁸Division of Nutritional Epidemiology, Institute of Environmental Medicine, Karolinska Institutet, SE-171 77 Stockholm, Sweden

³⁹Department of Surgical Sciences, Uppsala University, 75185 Uppsala, Sweden

⁴⁰Division of Cancer Epidemiology and Genetics, National Cancer Institute, NIH, Bethesda, MD 20892, USA

⁴¹Cancer Epidemiology Unit, Nuffield Department of Population Health, University of Oxford, Oxford, OX3 7LF, UK

⁴²Division of Epidemiology, Department of Medicine, Vanderbilt University Medical Center,
 2525 West End Avenue, Suite 600, Nashville, TN 37232 USA.

⁴³International Epidemiology Institute, Rockville, MD 20850, USA

⁴⁴Division of Epidemiology, Department of Medicine, Vanderbilt University Medical Center, 2525 West End Avenue, Suite 800, Nashville, TN 37232 USA.

⁴⁵Department of Family and Community Medicine, Meharry Medical College, 1005 Dr. DB Todd Jr. Blvd., Nashville, TN 37208 USA

⁴⁶Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, Washington, 98109-1024, USA

⁴⁷Department of Epidemiology, School of Public Health, University of Washington, Seattle, Washington 98195, USA

⁴⁸Department of Epidemiology, Harvard T. H. Chan School of Public Health, Boston, MA 02115, USA

⁴⁹Division of Cancer Sciences, University of Manchester, Manchester Academic Health Science Centre, Radiotherapy Related Research, The Christie Hospital NHS Foundation Trust, Manchester, M13 9PL UK

⁵⁰Division of Urologic Surgery, Brigham and Womens Hospital, 75 Francis Street, Boston, MA 02115, USA

⁵¹Sorbonne Universite, GRC n°5, AP-HP, Tenon Hospital, 4 rue de la Chine, F-75020 Paris, France

⁵²CeRePP, Tenon Hospital, Paris, France.

⁵³Division of Cancer Epidemiology and Genetics, National Cancer Institute, NIH, Bethesda, MD, USA

⁵⁴Department of Molecular Medicine, Aarhus University Hospital, Palle Juul-Jensen Boulevard 99, 8200 Aarhus N, Denmark

⁵⁵Department of Clinical Medicine, Aarhus University, DK-8200 Aarhus N

⁵⁶International Hereditary Cancer Center, Department of Genetics and Pathology, Pomeranian Medical University, Szczecin, Poland

⁵⁷Department of Medical Genetics, Oslo University Hospital, 0424 Oslo, Norway

⁵⁸Cancer & Environment Group, Center for Research in Epidemiology and Population Health

(CESP), INSERM, University Paris-Sud, University Paris-Saclay, 94807 Villejuif Cédex, France ⁵⁹Paris-Sud University, UMRS 1018, 94807 Villejuif Cedex, France

⁶⁰Clinical Gerontology Unit, University of Cambridge, Cambridge, CB2 2QQ, UK

⁶¹Department of Cancer Epidemiology, Moffitt Cancer Center, 12902 Magnolia Drive, Tampa, FL 33612, USA

⁶²Department of Preventive Medicine, Keck School of Medicine, University of Southern California/Norris Comprehensive Cancer Center, Los Angeles, California, USA

⁶³Humangenetik Tuebingen, Paul-Ehrlich-Str 23, D-72076 Tuebingen, Germany

⁶⁴Dept. of Surgical Oncology, Princess Margaret Cancer Centre, Toronto ON M5G 2M9, Canada
 ⁶⁵Dept. of Surgery (Urology), University of Toronto, Canada

⁶⁶Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN 55905, USA
 ⁶⁷Department of Radiation Oncology and Department of Genetics and Genomic Sciences, Box
 1236, Icahn School of Medicine at Mount Sinai, One Gustave L. Levy Place, New York, NY

10029, USA

⁶⁸Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, NY 10029-5674, USA.

⁶⁹Centre for Molecular Oncology, Barts Cancer Institute, Queen Mary University of London, John Vane Science Centre, Charterhouse Square, London, EC1M 6BQ, UK

⁷⁰Uro Care, Kampala, Uganda

⁷¹Fundación Pública Galega Medicina Xenómica, Santiago De Compostela, 15706, Spain

⁷²Instituto de InvestigaciónSanitaria de Santiago de Compostela, Santiago De Compostela, 15706, Spain.

⁷³Centro de Investigaciónen Red de Enfermedades Raras (CIBERER), Spain

⁷⁴Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA

⁷⁵Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, 450 West Drive, CB 7295, Chapel Hill, NC 27599, USA

⁷⁶Department of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA

⁷⁷http://impact.icr.ac.uk

⁷⁸ISGlobal, Barcelona, Spain

⁷⁹IMIM (Hospital del Mar Medical Research Institute), Barcelona, Spain

⁸⁰Universitat Pompeu Fabra (UPF), Barcelona, Spain

⁸¹Channing Division of Network Medicine, Department of Medicine, Brigham and Women's Hospital/Harvard Medical School, Boston, MA 02184, USA

⁸²The University of Texas M. D. Anderson Cancer Center, 1515 Holcombe Blvd., Houston, TX 77030, USA

⁸³Department of Genetics, Portuguese Oncology Institute of Porto (IPO-Porto), Porto, Portugal

⁸⁴Biomedical Sciences Institute (ICBAS), University of Porto, Porto, Portugal

⁸⁵Univ Rennes, Inserm, EHESP, Irset (Institut de recherche en santé, environnement et travail) -UMR_S 1085, Rennes, France

⁸⁶Department of Urology, Mays Cancer Center, University of Texas Health Science Center at San Antonio, San Antonio Texas

⁸⁷Division of Epidemiology, Department of Internal Medicine, University of Utah School of Medicine, Salt Lake City, Utah, USA

⁸⁸George E. Wahlen Department of Veterans Affairs Medical Center, Salt Lake City, Utah 84148, USA

⁸⁹Division of Clinical Epidemiology and Aging Research, German Cancer Research Center (DKFZ), D-69120, Heidelberg, Germany

⁹⁰German Cancer Consortium (DKTK), German Cancer Research Center (DKFZ), D-69120 Heidelberg, Germany

⁹¹Division of Preventive Oncology, German Cancer Research Center (DKFZ) and National Center for Tumor Diseases (NCT), Im Neuenheimer Feld 460 69120 Heidelberg, Germany

⁹²Department of Medicine, Division of Oncology, Stanford Cancer Institute, Stanford University School of Medicine, Stanford, 780 Welch Road, CJ250C, CA 94304-5769

⁹³Molecular Medicine Center, Department of Medical Chemistry and Biochemistry, Medical University of Sofia, Sofia, 2 Zdrave Str., 1431 Sofia, Bulgaria

⁹⁴The University of Texas M. D. Anderson Cancer Center, Department of Genitourinary Medical Oncology, 1515 Holcombe Blvd., Houston, TX 77030, USA

⁹⁵Department of Population Sciences, Beckman Research Institute of the City of Hope, 1500 East Duarte Road, Duarte, CA 91010, 626-256-HOPE (4673)

⁹⁶Ghent University, Faculty of Medicine and Health Sciences, Basic Medical Sciences, Proeftuinstraat 86, B-9000 Gent

⁹⁷The University of Surrey, Guildford, Surrey, GU2 7XH

⁹⁸Department of Surgery, Faculty of Medicine, University of Malaya, 50603 Kuala Lumpur, Malaysia

⁹⁹Department of Urology, University of Washington, 1959 NE Pacific Street, Box 356510, Seattle, WA 98195, USA

¹⁰⁰Department of Medicine and Urologic Surgery, Vanderbilt University Medical Center, 1211 Medical Center Drive, Nashville, TN 37232, USA

¹⁰¹Division of Medical Oncology, Urogenital Unit, Department of Oncology, University Hospital Centre Zagreb, University of Zagreb, School of Medicine, 10 000 Zagreb, Croatia

¹⁰²Department of Oncology, Cross Cancer Institute, University of Alberta, 11560 University Avenue, Edmonton, Alberta, Canada T6G 1Z2

¹⁰³Division of Radiation Oncology, Cross Cancer Institute, 11560 University Avenue, Edmonton, Alberta, Canada T6G 1Z2

¹⁰⁴Molecular Endocrinology Laboratory, Department of Cellular and Molecular Medicine, KU Leuven, BE-3000, Belgium

 ¹⁰⁵Genomic Medicine Group, Galician Foundation of Genomic Medicine, Instituto de Investigacion Sanitaria de Santiago de Compostela (IDIS), Complejo Hospitalario Universitario de Santiago, Servicio Galego de Saúde, SERGAS, 15706, Santiago de Compostela, Spain
 ¹⁰⁶University of California San Diego, Moores Cancer Center, La Jolla, CA 92037, USA

¹⁰⁷Division of Cancer Sciences, Manchester Cancer Research Centre, Faculty of Biology, Medicine and Health, Manchester Academic Health Science Centre, NIHR Manchester

Biomedical Research Centre, Health Innovation Manchester, University of Manchester, M13 9WL

¹⁰⁸Case Western Reserve University, Department of Population and Quantitative Health Sciences, Cleveland Institute for Computational Biology, 2103 Cornell Road, Wolstein Research Building, Suite 2527, Cleveland, OH, 44106 USA

¹⁰⁹Uniformed Services University, 4301 Jones Bridge Rd, Bethesda, MD 20814, USA

¹¹⁰Center for Prostate Disease Research, 1530 East Jefferson Street, Rockville, MD 20852, USA

¹¹¹Department of Clinical Chemistry, Erasmus University Medical Center, 3015 CE Rotterdam, The Netherlands

¹¹²Epidemiology and Biostatistics Unit, Centre Armand-Frappier Santé Biotechnologie, Institut national de la recherche scientifique, 531 Boul. des Prairies, Laval, OC, Canada H7V 1B7

¹¹³Department of Social and Preventive Medicine, School of Public Health, University of Montreal, Montreal, QC, Canada

¹¹⁴The University of Miami School of Medicine, Sylvester Comprehensive Cancer Center, 1120 NW 14th Street, CRB 1511, Miami, Florida 33136, USA

¹¹⁵http://www.cancerresearchuk.org/about-cancer/find-a-clinical-trial/a-study-find-out-lookinggene-changes-would-be-useful-in-screening-for-prostate-cancer-profile-pilot ¹¹⁶Nuffield Department of Surgical Sciences, University of Oxford, Oxford, UK

¹¹⁷NORMENT. KG Jebsen Centre, Oslo University Hospital and University of Oslo, Oslo, Norway

¹¹⁸Department of Radiology, University of California San Diego, La Jolla, CA, USA

¹¹⁹Department of Bioengineering, University of California San Diego, La Jolla, CA, USA

* Additional members from the Prostate Cancer Association Group to Investigate Cancer Associated Alterations in the Genome consortium (PRACTICAL, http://practical.icr.ac.uk/) are provided in the Supplemental Material.

Key words: prostate cancer: ethnicity: genetics: precision medicine: survival: hazard: risk factors

Corresponding Author:

Tyler M. Seibert, MD, PhD Assistant Professor Department of Radiation Medicine and Applied Sciences Department of Bioengineering University of California San Diego 9500 Gilman Dr. Mail Code 0861 La Jolla, CA 92093-0861 tseibert@ucsd.edu

Summary boxes

What is already known on this topic

- Genetic risk stratification can identify men with greater predisposition for developing prostate cancer, but these risk models may worsen health disparities, as most have only been validated for men of European ancestry
- A polygenic hazard score was previously associated with age at prostate cancer diagnosis and improved PCa screening accuracy in Europeans
- Performance of the polygenic hazard score in multi-ethnic populations is unknown

What this study adds

- In a dataset from 80,491 men of various self-reported race/ethnicities, the polygenic hazard score was associated with age at prostate cancer diagnosis, aggressive prostate cancer diagnosis, and prostate cancer death.
- PHS stratifies men of European, Asian, and African ancestry by genetic risk for any, aggressive, and fatal prostate cancer.

Abstract

Objectives: A polygenic hazard score (PHS₁)—weighted sum of 54 single-nucleotide polymorphism genotypes—was previously associated with age at prostate cancer (PCa) diagnosis and improved PCa screening accuracy in Europeans. Performance in more diverse populations is unknown. We evaluated PHS association with PCa in multi-ethnic populations.

Design: PHS_1 was adapted for compatibility with genotype data from the OncoArray project (PHS₂) and tested for association with age at PCa diagnosis, at aggressive PCa diagnosis, and at PCa death.

Setting: Multiple international institutions.

Participants: Men with available OncoArray data from the PRACTICAL consortium who were not included in PHS₁ development/validation.

Main Outcomes and Measures: PHS_2 was tested via Cox proportional hazards models for age at PCa diagnosis, age at aggressive PCa diagnosis (any of: Gleason score \geq 7, stage T3-T4, $PSA\geq$ 10 ng/mL, nodal/distant metastasis), and age at PCa-specific death.

<u>Results</u>: 80,491 men of various self-reported race/ethnicities were included (30,575 controls, 49,916 PCa cases; genetic ancestry groups: 71,856 European, 6,253 African, 2,382 Asian). Median age at last follow-up was 70 years (IQR 63-76); 3,983 PCa deaths, 5,806 other deaths, 70,702 still alive. PHS₂ had 46 polymorphisms: 24 directly genotyped and 22 acceptable proxies

 $(r^2 \ge 0.94)$. PHS₂ was associated with age at PCa diagnosis in the multi-ethnic dataset (z=54, p<10⁻¹⁶) and in each genetic ancestry group: European (z=56, p<10⁻¹⁶), Asian (z=47, p<10⁻¹⁶), African (z=29, p<10⁻¹⁶). PHS₂ was also associated with age at aggressive PCa diagnosis in each genetic ancestry group (p<10⁻¹⁶) and with age of PCa death in the full dataset (p<10⁻¹⁶). Comparing the 80th and 20th percentiles of genetic risk, men with high PHS had hazard ratios of 5.3 [95% CI: 5.0-5.7], 5.9 [5.5-6.3], and 5.7 [4.6-7.0] for PCa, aggressive PCa, and PCa-specific death, respectively. Within European, Asian, and African ancestries, analogous hazard ratios for PCa were 5.5 [5.2-5.9], 4.5 [3.2-6.3], and 2.5 [2.1-3.1], respectively.

<u>**Conclusions**</u>: PHS_2 is strongly associated with age at PCa diagnosis in a multi-ethnic dataset. PHS₂ stratifies men of European, Asian, and African ancestry by genetic risk for any, aggressive, and fatal PCa.

Introduction

Prostate cancer (PCa) is the second most common cancer diagnosed in men worldwide, causing substantial morbidity and mortality¹. PCa screening may reduce morbidity and mortality^{2–5}, but to avoid overdiagnosis and overtreatment of indolent disease^{6–9}, it should be targeted and personalized. PCa age at diagnosis is important for clinical decisions regarding if/when to initiate screening for an individual^{10,11}. Survival is another key cancer endpoint recommended for risk models¹².

Genetic risk stratification is promising for identifying individuals with greater predisposition for developing cancer¹³⁻¹⁶, including PCa¹⁷. Polygenic models use common variants—identified in genome-wide association studies—whose combined effects can assess overall risk of disease development^{18,19}. Recently, a polygenic hazard score (PHS) was developed as a weighted sum of 54 single-nucleotide polymorphisms (SNPs) that models a man's genetic predisposition for developing PCa¹³. Validation testing was done using ProtecT trial data² and demonstrated the PHS to be associated with age at PCa diagnosis, including aggressive PCa¹³. However, the development and validation datasets were limited to men of European ancestry. While genetic risk models might be important clinical tools for prognostication and risk stratification, using them may worsen health disparities²⁰⁻²⁴ because most models are constructed using European data and may underrepresent genetic variants important in persons of non-European ancestry²⁰⁻²⁴. Indeed, this is particularly concerning in PCa, as race/ethnicity is an important PCa risk factor; diagnostic, treatment, and outcomes disparities continue to exist between different races/ethnicities^{25,26}.

11

Here, we assessed PHS performance in a multi-ethnic dataset that includes individuals of European, African, and Asian genetic ancestry. This dataset also includes long-term follow-up information, affording an opportunity to evaluate PHS for association with fatal PCa.

Methods

Participants

We obtained data from the OncoArray project²⁷ that had undergone quality control steps described previously¹⁸. This dataset includes 91,480 men with genotype and phenotype data from 64 studies (**Supplemental Methods**). Individuals whose data were used in the prior development or validation of the original PHS model (PHS₁) were excluded $(n=10,989)^{13}$, leaving 80,491 in the independent dataset used here. **Table 1** describes available data. Individuals not meeting the endpoint for each analysis were censored at age of last follow-up.

All contributing studies were approved by the relevant ethics committees; written informed consent was acquired from the study participants²⁸. The present analyses used deidentified data from the PRACTICAL consortium.

Polygenic Hazard Score (PHS)

The original PHS₁ was validated for association with age at PCa diagnosis in men of European ancestry, using a survival analysis¹³. To ensure the score was not simply identifying men at risk of indolent disease, PHS₁ was also validated for association with age at aggressive PCa (defined as intermediate-risk disease, or above⁶) diagnosis¹³. PHS₁ was calculated as the vector product of a patient's genotype (X_i) for *n* selected SNPs and the corresponding parameter estimates (β_i) from a Cox proportional hazards regression:

$$PHS = \sum_{i}^{n} Xi \beta i \tag{1}$$

The 54 SNPs in PHS₁ were selected using PRACTICAL consortium data (n=31,747 men) genotyped with a custom array (iCOGS, Illumina, San Diego, CA)¹³.

Genetic Ancestry Determination

Self-reported race/ethnicities^{27,29} included European, East Asian, African American, Hawaiian, Hispanic American, South Asian, Black African, Black Caribbean, and Other. Genetic ancestry (European, African, or Asian) for all individuals was used for the present analyses because it is objective and may be more informative than self-reported race/ethnicities³⁰

(Supplemental Methods).

Adapting the PHS to OncoArray

Genotyping for the present study was performed using a commercially-available, cancerspecific array (OncoArray, Illumina, San Diego, CA)¹⁸. Twenty-four of the 54 SNPs in PHS₁ were directly genotyped on OncoArray. We identified proxy SNPs for those not directly genotyped and re-calculated the SNP weights in the same dataset used for the original development of PHS₁¹³ (**Supplemental Methods**).

The performance of this new, adapted PHS (PHS₂), was compared to that of PHS₁ in the ProtecT dataset originally used to validate PHS₁ (n=6,411). PHS₂ was calculated for all patients in the ProtecT validation set and was tested as the sole predictive variable in a Cox proportional hazards regression model (R v.3.5.1, "survival" package³¹) for age at aggressive PCa diagnosis, the primary endpoint of that study. Performance was assessed by the metrics reported during the PHS₁ development¹³: *z*-score and hazard ratio (HR_{98/50}) for aggressive PCa between men in the

highest 2% of genetic risk (\geq 98th percentile) vs. those with average risk (30th-70th percentile). HR 95% confidence intervals (CIs) were determined by bootstrapping 1,000 random samples from the ProtecT dataset^{32,33}, while maintaining the same number of cases and controls. PHS₂ percentile thresholds are shown in the **Supplement**.

Any PCa

We tested PHS_2 for association with age at diagnosis of any PCa in the multi-ethnic dataset (n=80,491, **Table 1**).

PHS₂ was calculated for all patients in the multi-ethnic dataset and used as the sole independent variable in Cox proportional hazards regressions for the endpoint of age at PCa diagnosis. Due to the potential for Cox proportional hazards results to be biased by a higher number of cases in our dataset than in the general population, sample-weight corrections were applied to all Cox models^{13,34} (**Supplemental Methods**). Significance was set at α =0.01, and pvalues reported were truncated at <10⁻¹⁶, if applicable¹³.

These Cox proportional hazards regressions (with PHS₂ as the sole independent variable and age at PCa diagnosis as the outcome) were then repeated for subsets of data, stratified by genetic ancestry: European, Asian, and African. Percentiles of genetic risk were calculated as done previously¹³, using data from the 9,728 men in the original (iCOGS) development set who were less than 70 years old and without PCa. Hazard ratios (HRs) and 95% CIs for each genetic ancestry group were calculated to make the following comparisons: HR_{98/50}, men in the highest 2% of genetic risk vs. those with average risk (30^{th} - 70^{th} percentile); HR_{80/50}, men in the highest 20% vs. those with average risk, HR_{20/50}, men in the lowest 20% vs. those with average risk; and HR_{80/20}, men in the highest 20% vs. lowest 20%. CIs were determined by bootstrapping 1,000 random samples from each genetic ancestry group^{32,33}, while maintaining the same number of cases and controls. HRs and CIs were calculated for age at PCa diagnosis separately for each genetic ancestry group.

Given that the overall incidence of PCa in different populations varies, we performed a sensitivity analysis of the population case/control numbers, allowing the population incidence to vary from 25% to 400% of that reported in Sweden (as an example population; **Supplemental Methods**).

Aggressive PCa

Recognizing that not all PCa is clinically significant, we also tested PHS_2 for association with age at aggressive PCa diagnosis in the multi-ethnic dataset. For these analyses, we included cases that had known tumor stage, Gleason score, and PSA at diagnosis (n=60,617 cases, **Table 1**). Aggressive PCa cases were those that met any of the following previously defined criteria for aggressive disease^{6,13}: Gleason score \geq 7, PSA \geq 10 ng/mL, T3-T4 stage, nodal metastases, or distant metastases (**Supplemental Methods**). As before, Cox proportional hazards models and sensitivity analysis were used to assess association.

Fatal PCa

Using an even stricter definition of clinical significance, we then evaluated association of PHS_2 with age at PCa death in the multi-ethnic dataset. All cases (regardless of staging completeness) and controls were included, and the endpoint was age at death due to PCa. This analysis was not stratified by genetic ancestry due to low numbers of recorded PCa deaths in the non-European datasets. Cause of death was determined by the investigators of each contributing

study using cancer registries and/or medical records (**Supplemental Methods**). At last followup, 3,983 men had died from PCa, 5,806 had died from non-PCa causes, and 70,702 were still alive. The median age at last follow-up was 70 years (IQR 63-76). As before, Cox proportional hazards models and sensitivity analysis were used to assess association.

PHS and Family History

Family history (presence/absence of a first-degree relative with a PCa diagnosis) was also tested for association with any, aggressive, or fatal PCa. There were 46,030 men with available PCa family history data.

Cox proportional hazards models were used to assess family history for association with any, aggressive, or fatal PCa. To evaluate the relative importance of each, a multivariable model using both family history and PHS was compared to using family history alone (log-likelihood test; α =0.01). HRs were calculated for each variable.

Results

Adaption of PHS for OncoArray

Of the 30 SNPs from PHS₁ not directly genotyped on OncoArray, proxy SNPs were identified for 22 (linkage disequilibrium \geq 0.94). Therefore, PHS₂ included 46 SNPs, total (**Supplemental Results**). PHS₂ association with age at aggressive PCa diagnosis in ProtecT was similar to that previously reported for PHS₁ (*z*=22 for PHS₁, *z*=21 for PHS₂, each *p*<10⁻¹⁶). HR_{98/50} was 4.7 [95% CI: 3.6-6.1] for PHS₂, compared to 4.6 [3.5-6.0] for PHS₁.

Any PCa

PHS₂ was associated with age at PCa diagnosis in all three genetic ancestry groups (**Table 2**). Comparing the 80th and 20th percentiles of genetic risk, men with high PHS had a HR of 5.3 [5.0-5.7] for any PCa. Within each genetic ancestry group, men with high PHS had HRs of 5.5 [5.2-5.9], 4.5 [3.2-6.3], and 2.5 [2.1-3.1] for men of European, Asian, and African ancestry, respectively.

Aggressive PCa

PHS₂ was associated with age at aggressive PCa diagnosis in all three genetic ancestry groups (**Table 3**). Comparing the 80th and 20th percentiles of genetic risk, men with high PHS had a HR of 5.9 [5.5-6.3] for aggressive PCa; within each genetic ancestry group, men with high PHS had HRs of 5.6 [5.2-6.0], 5.2 [4.8-5.6], and 2.4 [2.3-2.6] for men of European, Asian, and African ancestry, respectively.

Fatal PCa

PHS₂ was associated with age at PCa death for all men in the multi-ethnic dataset (z=16, $p<10^{-16}$). **Table 4** shows *z*-scores and corresponding HRs for fatal PCa. Comparing the 80th and 20th percentiles of genetic risk, men with high PHS had a HR of 5.7 [4.6-7.0] for PCa death.

Sensitivity Analyses

Sensitivity analyses demonstrated that large changes in assumed population incidence had minimal effect on the calculated HRs for any, aggressive, or fatal PCa (**Supplemental Results**).

PHS and Family History

Family history was also associated with any PCa (z=40, $p<10^{-16}$; **Table 5**), aggressive PCa (z=32, $p<10^{-16}$), and fatal PCa (z=16, $p<10^{-16}$) in the multi-ethnic dataset. Among those with known family history, the combination of family history and PHS performed better than family history alone (log-likelihood $p<10^{-16}$). This pattern held true when analyses were repeated on each genetic ancestry. Additional family history analyses are reported in the **Supplemental Results**.

Discussion

These results confirm the previously reported association of PHS with age at PCa diagnosis in Europeans and show that this finding generalizes to a multi-ethnic dataset, including men of European, Asian, and African genetic ancestry. PHS is also associated with age at aggressive PCa diagnosis and at PCa death. Comparing the highest and lowest quintiles of genetic risk, men with high PHS had HRs of 5.3, 5.9, and 5.7 for any PCa, aggressive PCa, and PCa death, respectively.

We found that PHS is associated with PCa in men of European, Asian, and African genetic ancestry (and a wider range of self-reported race/ethnicities). Current PCa screening guidelines suggest possible initiation at earlier ages for men of African ancestry, given higher incidence rates and worse survival when compared to men of European ancestry²⁶. Using the PHS to risk-stratify men might help with decisions regarding when to initiate PCa screening: perhaps a man with African genetic ancestry in the lowest percentiles of genetic risk by PHS could safely delay or forgo screening to decrease the possible harms associated with overdetection and overtreatment⁹, while a man in the highest risk percentiles might consider

18

screening at an earlier age. Similar reasoning applies to men of all genetic ancestries. Riskstratified screening should be prospectively evaluated.

PHS performance was better in those with European and Asian genetic ancestry than in those with African ancestry. For example, comparing the highest and lowest quintiles of genetic risk, men with of European and Asian genetic ancestry with high PHS had HRs for any PCa of 5.5 and 4.5 times, respectively, while the analogous HR for men of African genetic ancestry was 2.5 (similar trends were seen for aggressive PCa). This suggests PHS can differentiate men of higher and lower risk in each ancestral group, but the range of risk levels may be narrower in those of African ancestry. Possible reasons for relatively diminished performance include increased genetic diversity with less linkage disequilibrium in those of African genetic ancestry^{35–37}. Known health disparities may also contribute²⁵, as the availability—and timing—of PSA results may depend on healthcare access. Alarmingly, there has historically been poor representation of African populations in clinical or genomic research studies^{20,21}. This pattern is reflected in the present study, where most men of African genetic ancestry were missing clinical diagnosis information used to determine disease aggressiveness. That such clinical information is less available for men of African ancestry also leaves open the possibility of systematic differences in the diagnostic workup—and therefore age of diagnosis—across different ancestry populations. Notwithstanding these caveats, the present PHS is associated with age at PCa diagnosis in men of African ancestry, possibly paving the way for more personalized screening decisions for men of African descent.

The first PHS validation study used data from ProtecT, a large PCa trial^{2,13}. ProtecT's screening design yielded biopsy results from both controls and cases with PSA \geq 3 ng/mL, making it possible to demonstrate improved accuracy and efficiency of PCa screening with PSA

19

testing. Limitations of the ProtecT analysis, though, include few recorded PCa deaths in the available data, and the exclusion of advanced cancer from that trial². The present study includes long-term observation, with both early and advanced disease¹⁸, allowing for evaluation of PHS association with any, aggressive, and fatal PCa; we found PHS to be associated with all outcomes.

Age is critical in clinical decisions of whether men should be offered PCa screening³⁸⁻⁴⁰ and in how to treat men diagnosed with PCa^{38,39}. Age may also inform prognosis^{39,41}. Age at diagnosis or death is therefore of clinical interest in inferring how likely a man is to develop cancer at an age when he may benefit from treatment. One important advantage of the survival analysis used here is that it permits men without cancer at time of last follow-up to be censored, while allowing for the possibility of them developing PCa (including aggressive or fatal PCa) later on. PCa death is a hard endpoint with less uncertainty than clinical diagnosis (which may vary with screening practices and delayed medical attention). PHS may help identify men with high (or low) genetic predisposition to develop lethal PCa and could assist physicians deciding when to initiate screening.

Current guidelines suggest considering a man's individual cancer risk factors, overall life expectancy, and medical comorbidities when deciding whether to screen⁶. The most prominent clinical risk factors used in practice are family history and race/ethnicity^{6,42,43}. Combined PHS and family history performed better than either alone in this multi-ethnic dataset. This finding is consistent with a prior report that PHS adds considerable information over family history alone. The prior study did not find an association of family history with age at PCa diagnosis, perhaps because the universal screening approach of the ProtecT trial diluted the influence of family history on who is screened in typical practice¹³. In the present study, family history and PHS

appear complementary in assessing PCa genetic risk. Moreover, the HRs for PHS suggest clinical relevance similar or greater to predictive tools routinely used for cancer screening (e.g., breast cancer) and for other diseases (e.g., diabetes and cardiovascular disease). HRs reported for those tools are around 1-3 for disease development or other adverse outcome⁴⁴⁻⁴⁸; HRs reported here for PHS (for any, aggressive, or fatal PCa) are similar or greater.

Limitations to this work include that the dataset comes from multiple, heterogeneous studies, from various populations with variable screening rates. This allowed for a large, multiethnic dataset that includes clinical and survival data, but comes with uncertainties avoided in the ProtecT dataset used for original validation. However, the heterogeneity would likely reduce the PHS performance, not systematically inflate the results. Second, we note that no germline SNP tool, including this PHS, has been shown to discriminate men at risk of aggressive PCa from those at risk of only indolent PCa. Third, while the genetic ancestry classifications used here may be more accurate than self-reported race/ethnicity alone³⁰, possible admixed genetic ancestry within individuals was not assessed; future development will consider local ancestry. As noted above, clinical data availability was not uniform across contributing studies and was lower in men of African genetic ancestry. The PHS may not include all SNPs associated with PCa; in fact, more such SNPs have been reported since the development of the original PHS¹⁸, some specifically within non-European populations^{49–51}. Further model optimization (possibly by incorporating additional SNPs) may improve PCa risk stratification. Future work could also evaluate the PHS performance in relation to epidemiological risk factors previously associated with PCa risk beyond those currently used in clinical practice (i.e., family history and race/ethnicity). Finally, various circumstances and disease-modifying treatments may have influenced post-diagnosis survival to unknown degree. Despite this possible source of variability

21

in survival among men with fatal PCa, PHS was still associated with age at death, an objective and meaningful endpoint. Future development and optimization hold promise for improving upon the encouraging risk stratification achieved here in men of different genetic ancestries, particularly African.

Conclusion

In a multi-ethnic dataset comprising men of European, Asian and African ancestry, PHS was associated with age at PCa diagnosis, as well as age at aggressive PCa diagnosis, and at death from PCa. PHS performance was relatively diminished in men of African genetic ancestry, compared to performance in men of European or Asian genetic ancestry. PHS risk-stratifies men of European, Asian and African ancestry and should be prospectively studied as a means to individualize screening strategies seeking to reduce PCa morbidity and mortality.

References

- Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. *CA Cancer J Clin*. 2015;65(2):87-108. doi:10.3322/caac.21262
- Hamdy FC, Donovan JL, Lane JA, et al. 10-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Localized Prostate Cancer. *N Engl J Med.* 2016;375(15):1415-1424. doi:10.1056/NEJMoa1606220
- Bill-Axelson A, Holmberg L, Garmo H, et al. Radical Prostatectomy or Watchful Waiting in Prostate Cancer — 29-Year Follow-up. *N Engl J Med.* 2018;379(24):2319-2329. doi:10.1056/NEJMoa1807801
- Bolla M, de Reijke TM, Van Tienhoven G, et al. Duration of Androgen Suppression in the Treatment of Prostate Cancer. *N Engl J Med.* 2009;360(24):2516-2527. doi:10.1056/NEJMoa0810095
- Jones CU, Hunt D, McGowan DG, et al. Radiotherapy and Short-Term Androgen Deprivation for Localized Prostate Cancer. *N Engl J Med.* 2011;365(2):107-118. doi:10.1056/NEJMoa1012348
- 6. NCCN Clinical Practice Guidelines in Oncology. Prostate Cancer. Version 1.2019.
- Grossman DC, Curry SJ, Owens DK, et al. Screening for prostate cancer: US Preventive Services Task Force recommendation statement. *JAMA*. 2018;319(18):1901-1913. doi:10.1001/jama.2018.3710
- Wolf AMD, Wender RC, Etzioni RB, et al. American Cancer Society Guideline for the Early Detection of Prostate Cancer: Update 2010. *CA Cancer J Clin.* 2010;60(2):70-98. doi:10.3322/caac.20066
- 9. Ilic D, Neuberger MM, Djulbegovic M, Dahm P. Screening for prostate cancer. *Cochrane*

Database Syst Rev. 2013;(1):CD004720. doi:10.1002/14651858.CD004720.pub3

- Stangelberger A, Waldert M, Djavan B. Prostate cancer in elderly men. *Rev Urol*.
 2008;10(2):111-119. http://www.ncbi.nlm.nih.gov/pubmed/18660852. Accessed July 22, 2019.
- 11. Leitzmann MF, Rohrmann S. Risk factors for the onset of prostatic cancer: Age, location, and behavioral correlates. *Clin Epidemiol*. 2012. doi:10.2147/CLEP.S16747
- Kattan MW, Hess KR, Amin MB, et al. American Joint Committee on Cancer acceptance criteria for inclusion of risk models for individualized prognosis in the practice of precision medicine. *CA Cancer J Clin.* 2016. doi:10.3322/caac.21339
- Seibert TM, Fan CC, Wang Y, et al. Polygenic hazard score to guide screening for aggressive prostate cancer: Development and validation in large scale cohorts. *BMJ*. 2018;360:1-7. doi:10.1136/bmj.j5757
- 14. Witte JS. Personalized prostate cancer screening: Improving PSA tests with genomic information. *Sci Transl Med.* 2010;2(62):62ps55. doi:10.1126/scitranslmed.3001861
- 15. Chen H, Liu X, Brendler CB, et al. Adding genetic risk score to family history identifies twice as many high-risk men for prostate cancer: Results from the prostate cancer prevention trial. *Prostate*. 2016;76(12):1120-1129. doi:10.1002/pros.23200
- Michailidou K, Hall P, Gonzalez-Neira A, et al. Large-scale genotyping identifies 41 new loci associated with breast cancer risk. *Nat Genet*. 2013;45(4):353-361.
 doi:10.1038/ng.2563
- Fantus RJ, Helfand BT. Germline genetics of prostate cancer: Time to incorporate genetics into early detection tools. *Clin Chem.* 2019;65(1):74-79. doi:10.1373/clinchem.2018.286658

- Schumacher FR, Al Olama AA, Berndt SI, et al. Association analyses of more than 140,000 men identify 63 new prostate cancer susceptibility loci. *Nat Genet*. 2018;50(7):928-936. doi:10.1038/s41588-018-0142-8
- Benafif S, Kote-Jarai Z, Eeles RA. A review of prostate cancer Genome-Wide Association Studies (GWAS). *Cancer Epidemiol Biomarkers Prev.* 2018. doi:10.1158/1055-9965.EPI-16-1046
- Martin AR, Kanai M, Kamatani Y, Okada Y, Neale BM, Daly MJ. Clinical use of current polygenic risk scores may exacerbate health disparities. *Nat Genet*. 2019;51(4):584-591. doi:10.1038/s41588-019-0379-x
- Duncan L, Shen H, Gelaye B, et al. Analysis of polygenic risk score usage and performance in diverse human populations. *Nat Commun.* 2019;10(1).
 doi:10.1038/s41467-019-11112-0
- Petrovski S, Goldstein DB. Unequal representation of genetic variation across ancestry groups creates healthcare inequality in the application of precision medicine. *Genome Biol.* 2016;17(1). doi:10.1186/s13059-016-1016-y
- 23. Grinde KE, Qi Q, Thornton TA, et al. Generalizing polygenic risk scores from Europeans to Hispanics/Latinos. *Genet Epidemiol*. 2019;43(1):50-62. doi:10.1002/gepi.22166
- 24. Popejoy AB, Fullerton SM. Genomics is failing on diversity. *Nature*.
 2016;538(7624):161-164. doi:10.1038/538161a
- DeSantis CE, Siegel RL, Sauer AG, et al. Cancer statistics for African Americans, 2016:
 Progress and opportunities in reducing racial disparities. *CA Cancer J Clin*.
 2016;66(4):290-308. doi:10.3322/caac.21340
- 26. Tsodikov A, Gulati R, Carvalho TM de, et al. Is prostate cancer different in black men?

Answers from three natural history models. *Cancer*. 2017;123(12):2312. doi:10.1002/CNCR.30687

- Amos CI, Dennis J, Wang Z, et al. The OncoArray consortium: A network for understanding the genetic architecture of common cancers. *Cancer Epidemiol Biomarkers Prev.* 2017;26(1):126-135. doi:10.1158/1055-9965.EPI-16-0106
- Kote-Jarai Z, Easton DF, Stanford JL, et al. Multiple novel prostate cancer predisposition loci confirmed by an international study: The PRACTICAL consortium. *Cancer Epidemiol Biomarkers Prev.* 2008;17(8):2052-2061. doi:10.1158/1055-9965.EPI-08-0317
- Li Y, Byun J, Cai G, et al. FastPop: A rapid principal component derived method to infer intercontinental ancestry using genetic data. *BMC Bioinformatics*. 2016;17(1). doi:10.1186/s12859-016-0965-1
- Marini S, Lena UK, Crawford KM, et al. Comparison of genetic and self-identified ancestry in modeling intracerebral hemorrhage risk. *Front Neurol*. 2018;9(514). doi:10.3389/fneur.2018.00514
- 31. R Core Team. R: A language and environment for statistical computing. In: *Vienna, Austria: R Foundation for Statistical Computing.*; 2015.
- 32. Efron B. Bootstrap Methods: Another Look at the Jackknife. Ann Stat. 1979;7(1):1-26.
- Efron B, Tibshirani R. Bootstrap Methods for Standard Errors, Confidence Intervals, and Other Measures of Statistical Accuracy. Vol 1.; 1986. https://about.jstor.org/terms.
 Accessed February 6, 2020.
- Therneau TM, Li H. Computing the Cox Model for Case Cohort Designs. *Lifetime Data* Anal. 1999;5(2):99-112. doi:10.1023/A:1009691327335
- 35. Rotimi CN, Bentley AR, Doumatey AP, Chen G, Shriner D, Adeyemo A. The genomic

landscape of African populations in health and disease. Hum Mol Genet.

2017;26(R2):R225-R236. doi:10.1093/hmg/ddx253

- Campbell MC, Tishkoff SA. African Genetic Diversity: Implications for Human Demographic History, Modern Human Origins, and Complex Disease Mapping. *Annu Rev Genomics Hum Genet*. 2008;9(1):403-433. doi:10.1146/annurev.genom.9.081307.164258
- Gomez F, Hirbo J, Tishkoff SA. Genetic variation and adaptation in Africa: Implications for human evolution and disease. *Cold Spring Harb Perspect Biol*. 2014;6(7). doi:10.1101/cshperspect.a008524
- 38. NCCN Guidelines Version 1.2019 Older Adult Oncology.; 2019.
- Bechis SK, Carroll PR, Cooperberg MR. Impact of age at diagnosis on prostate cancer treatment and survival. *J Clin Oncol*. 2011. doi:10.1200/JCO.2010.30.2075
- 40. Huynh□Le M, Myklebust TÅ, Feng CH, et al. Age dependence of modern clinical risk groups for localized prostate cancer—A population □ based study. *Cancer*. 2020. doi:10.1002/cncr.32702
- Pettersson A, Robinson D, Garmo H, Holmberg L, Stattin P. Age at diagnosis and prostate cancer treatment and prognosis: A population-based cohort study. *Ann Oncol.* 2018. doi:10.1093/annonc/mdx742
- 42. Giri VN, Beebe-Dimmer JL. Familial prostate cancer. *Semin Oncol*. 2016;43(5):560-565. doi:10.1053/j.seminoncol.2016.08.001
- 43. Ankerst DP, Hoefler J, Bock S, et al. Prostate cancer prevention trial risk calculator 2.0 for the prediction of low- vs high-grade prostate cancer. *Urology*. 2014;83(6):1362-1367. doi:10.1016/j.urology.2014.02.035
- 44. Brentnall AR, Cuzick J, Buist DSM, Bowles EJA. Long-Term accuracy of breast cancer

risk assessment combining classic risk factors and breast density. *JAMA Oncol.* 2018;4(9):e180174. doi:10.1001/jamaoncol.2018.0174

- 45. Yeh HC, Duncan BB, Schmidt MI, Wang NY, Brancati FL. Smoking, smoking cessation, and risk for type 2 diabetes mellitus: A cohort study. *Ann Intern Med.* 2010;152(1):10-17. doi:10.7326/0003-4819-152-1-201001050-00005
- Wang TJ, Larson MG, Levy D, et al. Plasma Natriuretic Peptide Levels and the Risk of Cardiovascular Events and Death. *N Engl J Med*. 2004;350(7):655-663. doi:10.1056/NEJMoa031994
- 47. Yang X, Leslie G, Gentry-Maharaj A, et al. Evaluation of polygenic risk scores for ovarian cancer risk prediction in a prospective cohort study. *J Med Genet*. 2018;55(8):546-554. doi:10.1136/jmedgenet-2018-105313
- 48. Torkamani A, Wineinger NE, Topol EJ. The personal and clinical utility of polygenic risk scores. *Nat Rev Genet*. 2018;19(9):581-590. doi:10.1038/s41576-018-0018-x
- Haiman CA, Chen GK, Blot WJ, et al. Characterizing genetic risk at known prostate cancer susceptibility loci in African Americans. *PLoS Genet*. 2011;7(5).
 doi:10.1371/journal.pgen.1001387
- Han Y, Signorello LB, Strom SS, et al. Generalizability of established prostate cancer risk variants in men of African ancestry. *Int J Cancer*. 2015;136(5):1210-1217. doi:10.1002/ijc.29066
- Cheng I, Chen GK, Nakagawa H, et al. Evaluating genetic risk for prostate cancer among Japanese and Latinos. *Cancer Epidemiol Biomarkers Prev.* 2012;21(11):2048-2058. doi:10.1158/1055-9965.EPI-12-0598
- 52. Klein JP, Houwelingen HC, Ibrahim JG ST, ed. Handbook of Survival Analysis. London:

Chapman and Hall/CRC; 2013.

	Genetic Ancestry						
	All	European	Asian	African			
Participants							
Controls	30,575	26,377	1,185	3,013			
Prostate cancer cases	49,916	45,479	1,197	3,240			
Aggressive prostate cancer cases ^a	26,419	24,279	716	1,424			
Fatal prostate cancer cases	3,983	3,908	57	18			
Number of Participants with Known First-Degree Family History Information							
Family history of	46,030	39,445	1,028	5,557			
prostate cancer	(28,204; 17,826)	(24,921; 14,524)	(519; 509)	(2,764; 2,793)			
available (prostate							
controls)							
· · · · ·	L						
Age Demographics							
Median age at	65 [60-71]	66 [60-71]	68 [62-74]	62 [56-68]			
diagnosis (IQR)							
Median age at last follow up (IQR ^b)	70 [63-76]	70 [64-77]	70 [63-76]	62 [56-68]			

Table 1. Participant characteristics, n=80,491.

^a Aggressive prostate cancer defined as Gleason score \geq 7, PSA \geq 10 ng/mL, T3-T4 stage, nodal metastases, or distant metastases.

^b IQR: interquartile range

Table 2: Association of PHS with prostate cancer. Hazard ratios (HRs) are shown comparing men in the highest 2% of genetic risk (\geq 98th percentile of PHS), highest 20% of genetic risk (\geq 80th percentile), average risk (30th-70th percentile), and lowest 20% of genetic risk (\leq 20th percentile) across genetic ancestry.

		Hazard ratios [95% CI] comparing percentiles of PHS ₂				
Genetic ancestry	z (p-value)	$\begin{array}{c} HR_{20/50}\text{:}\\ \leq 20^{\text{th}} \text{ vs } 30\text{-}70^{\text{th}} \end{array}$	$\begin{array}{c} HR_{80/50}:\\ \geq 80^{\text{th}} \text{ vs } 30-\\ 70^{\text{th}} \end{array}$	$\begin{array}{c} HR_{98/50}:\\ \geq 98^{th} \text{ vs } 30-\\ 70^{th}\end{array}$	$\begin{array}{c} HR_{80/20}\text{:}\\ \geq 80^{th} \text{ vs} \leq 20^{th} \end{array}$	
All	54 (<i>p</i> <10 ⁻¹⁶)	0.4	2.4	4.2	5.3	
(n=80,491)		[0.4, 0.5]	[2.3, 2.5]	[4.0, 4.5]	[5.0, 5.7]	
European	56 (<i>p</i> <10 ⁻¹⁶)	0.4	2.4	4.3	5.5	
(n=71,856)		[0.4, 0.5]	[2.4, 2.5]	[4.1, 4.6]	[5.2, 5.9]	
Asian	47 (<i>p</i> <10 ⁻¹⁶)	0.5	2.2	3.8	4.5	
(n=2,382)		[0.4, 0.6]	[1.8, 2.6]	[2.8, 5.1]	[3.2, 6.3]	
African	29 (<i>p</i> <10 ⁻¹⁶)	0.6	1.6	2.3	2.5	
(n=6,253)		[0.6, 0.7]	[1.4, 1.8]	[1.9, 2.7]	[2.1, 3.1]	

Table 3: Association of PHS with aggressive prostate cancer. Hazard ratios (HRs) are shown comparing men in the highest 2% of genetic risk ($\geq 98^{th}$ percentile of PHS), highest 20% of genetic risk ($\geq 80^{th}$ percentile), average risk (30^{th} - 70^{th} percentile), and lowest 20% of genetic risk ($\leq 20^{th}$ percentile) across genetic ancestry.

		Hazard ratios [95% CI] comparing percentiles of PHS ₂				
Genetic ancestry	z (p-value)	$\frac{HR_{20/50}}{\leq 20^{th} \text{ vs } 30\text{-}70^{th}}$	$\begin{array}{c} HR_{80/50}:\\ \geq 80^{\text{th}} \text{ vs } 30-\\ 70^{\text{th}} \end{array}$	$\begin{array}{c} HR_{98/50}:\\ \geq 98^{\text{th}} \text{ vs } 30-\\ 70^{\text{th}} \end{array}$	$\begin{array}{c} HR_{80/20}\text{:}\\ \geq \! 80^{th} vs \leq \! 20^{th} \end{array}$	
All (n=58,600)	48 (<i>p</i> <10 ⁻¹⁶)	0.4 [0.4, 0.4]	2.5 [2.4, 2.6]	4.6 [4.3, 4.9]	5.9 [5.5, 6.3]	
European (n=53,608)	46 (<i>p</i> <10 ⁻¹⁶)	0.5 [0.4, 0.5]	2.5 [2.4, 2.5]	4.4 [4.1, 4.7]	5.6 [5.2, 6.0]	
Asian (n=1,806)	44 (<i>p</i> <10 ⁻¹⁶)	0.5 [0.4, 0.5]	2.3 [2.2, 2.4]	4.1 [3.9, 4.4]	5.2 [4.8, 5.6]	
African (n=3,186)	24 (<i>p</i> <10 ⁻¹⁶)	0.6 [0.6, 0.7]	1.6 [1.5, 1.6]	2.2 [2.0, 2.3]	2.4 [2.3, 2.6]	

Table 4: Association of PHS with death from prostate cancer. Hazard ratios (HRs) are shown comparing men in the highest 2% of genetic risk ($\geq 98^{th}$ percentile of PHS), highest 20% of genetic risk ($\geq 80^{th}$ percentile), average risk (30^{th} - 70^{th} percentile), and lowest 20% of genetic risk ($\leq 20^{th}$ percentile).

		Hazard ratios [95% CI] comparing percentiles of PHS ₂			
Genetic ancestry	z (p-value)	$\frac{HR_{20/50}}{\leq 20^{\text{th}} \text{ vs } 30\text{-}70^{\text{th}}}$	$\begin{array}{c} HR_{80/50}:\\ \geq 80^{\text{th}} \text{ vs } 30-\\ 70^{\text{th}} \end{array}$	$\begin{array}{c} HR_{98/50}:\\ \geq 98^{th} \text{ vs } 30-\\ 70^{th}\end{array}$	$\begin{array}{c} HR_{80/20}:\\ \geq 80^{th} \ vs \leq 20^{th} \end{array}$
All (n=78,221)	16 (<i>p</i> <10 ⁻¹⁶)	0.4 [0.4, 0.5]	2.5 [2.2, 2.8]	4.5 [3.7, 5.4]	5.7 [4.6, 7.0]

Table 5: Multivariable models with both PHS and family history of prostate cancer (≥ 1 firstdegree relative affected, binary) for association with any prostate cancer in the multi-ethnic dataset, and by genetic ancestry. This analysis is limited to individuals with known family history. Both family history and PHS were significantly associated with any prostate cancer in the combined models. Hazard ratios (HRs) for family history were calculated as the exponent of the beta from the multivariable Cox proportional hazards regression⁵². The HR for PHS in the multivariable models was estimated as the HR_{80/20} (men in the highest 20% vs. those in the lowest 20% of genetic risk by PHS₂) in each cohort. The model with PHS performed better than family history alone (log-likelihood $p < 10^{-16}$).

Genetic Ancestry	Variable	beta	z-score	p-value	HR
All (n=46,030)	PHS	2.0	54	$< 10^{-16}$	4.5
	Family History	1.0	39	<10 ⁻¹⁶	2.5
European (n=39,445)	PHS	2.1	56	<10 ⁻¹⁶	4.8
	Family History	1.0	38	<10 ⁻¹⁶	2.5
Asian (n=1,028)	PHS	1.9	51	<10 ⁻¹⁶	4.2
	Family History	0.7	21	<10 ⁻¹⁶	2.1
African (n=5,557)	PHS	1.1	26	<10 ⁻¹⁶	2.2
	Family History	1.1	47	<10 ⁻¹⁶	3.1